查看購物車
  • English
  • Japanese
  • Korean
封面
市場調查報告書
商品編碼
1924661

Enzalutamide藥品市場依品牌類型、適應症、劑型、劑量強度、最終用戶及通路分類－2026-2032年全球預測

Enzalutamide Drugs Market by Brand Type, Indication, Formulation, Dosage Strength, End User, Distribution Channel - Global Forecast 2026-2032
出版日期: | 出版商: 360iResearch | 英文 190 Pages | 商品交期: 最快1-2個工作天內

價格

※ 本網頁內容可能與最新版本有所差異。詳細情況請與我們聯繫。

預計到 2025 年，Enzalutamide藥品市場價值將達到 69.7 億美元，到 2026 年將成長至 75 億美元，到 2032 年將達到 125.1 億美元，複合年成長率為 8.71%。

關鍵市場統計數據
基準年 2025 69.7億美元
預計年份：2026年 75億美元
預測年份 2032 125.1億美元
複合年成長率 (%) 8.71%

Enzalutamide的策略實施定位使其能夠適應不斷發展的臨床實踐、支付方優先事項和相互競爭的生命週期管理趨勢。

Enzalutamide已成為現代攝護腺癌治療的核心選擇之一，影響著多種疾病階段的治療路徑。近期臨床實踐的改變、監管核准的批准以及競爭對手的湧入，使得臨床討論的範圍從晚期轉移性疾病擴展到更早期的治療階段和輔助性治療治療領域。因此，價值鏈上的相關人員——包括臨床醫生、支付方、生產商和專科藥房——必須整合不斷更新的證據和實際營運情況，以確定其市場定位、獲取途徑和供應策略。本導言概述了恩札盧胺的核心藥理特性、一般臨床作用以及界定相關人員優先事項的策略要務，從而為更廣泛的背景分析奠定基礎。

不斷發展的臨床證據、監管細則和商業性創新將如何重塑Enzalutamide的使用和競爭動態

由於臨床證據的不斷更新、監管措施的調整以及商業性創新，Enzalutamide市場格局發生了顯著變化。臨床試驗和真實世界研究正在將治療討論擴展到疾病早期階段和複雜的患者亞群，迫使臨床醫生重新考慮治療順序和聯合用藥策略。同時，監管機構正在完善藥品附加檔和上市後核准要求，這影響處方模式以及生產商為維持市場接受度而必須提供的證據。這些臨床和監管趨勢正在推動商業模式的變革，這些變革強調患者援助計劃、數位化藥物管理工具和整合式護理路徑，以改善治療效果並減少就醫障礙。

評估近期關稅調整對癌症藥物籌資策略、供應鏈韌性和分銷模式的營運影響。

關稅措施的加強和貿易政策的更新為關鍵腫瘤治療藥物的生產商、經銷商和醫療服務提供者帶來了新的考慮。關稅分類的變化、活性藥物成分進口關稅的調整以及對跨境供應鏈日益嚴格的審查，都在影響採購決策和服務成本分析。這些政策變化促使各機構重新評估其製造地、供應商多元化策略和庫存管理政策，以降低貿易波動帶來的風險，同時確保依賴持續治療的患者的醫療服務不受影響。

將適應症細微差別、品牌類型、終端用戶行為和分銷管道差異與策略性市場行動聯繫起來的綜合細分分析

深入了解Enzalutamide市場區隔對於理解市場格局、制定針對患者族群、通路合作夥伴和產品組合的商業性和臨床策略至關重要。根據適應症，轉移性去勢抗性前列腺癌、轉移性荷爾蒙敏感性前列腺癌和非轉移性去勢抗性前列腺癌的價值提案必須有所區別。這是因為每種適應症都有其獨特的臨床終點、治療順序考量和支付方評估標準。根據品牌類型，核准的學名藥、品牌製劑和完全非品牌學名藥之間的策略選擇差異顯著，這會影響合約簽訂、定價策略和患者支援投入。根據最終用戶，醫院、零售藥局和專科癌症中心的供應和服務模式各不相同。醫院又分為私立和公立，專科癌症中心又分為大學附屬腫瘤中心和私立腫瘤中心。每種模式都有其自身的採購方式、臨床試驗合作和處理集管理。

區域監管差異、支付方生態系統和分銷基礎設施如何影響全球市場的准入路徑

區域趨勢在塑造藥物進入途徑、監管互動和商業策略方面發揮著至關重要的作用，美洲、歐洲、中東和非洲以及亞太地區呈現出鮮明的特徵。在美洲，市場進入往往由私人支付方和公共計畫共同推動，成熟的腫瘤網路和腫瘤專科藥房在分銷和病患支援方面發揮核心作用。支付者的談判和價值評估資料通常決定藥物是否被列入醫保目錄，而臨床指南的採納和學術機構的影響可以加速某些適應症的藥物推廣。相較之下，歐洲、中東和非洲擁有多元化的法規結構和報銷環境，既有集中式評估機制，也有國家層級的評估機制，導致該地區藥物進入時間和價格壓力各不相同。

競爭動態和夥伴關係模式凸顯了創新者、授權學名藥和服務供應商如何塑造治療方法差異化。

Enzalutamide領域的競爭格局呈現出多元化的特點，既有成熟的創新藥企，也有獲得授權的非專利參與企業、專科藥商和合約服務供應商，共同構成了一個日益複雜的多層次競爭環境。藥物研發公司致力於透過核准後臨床試驗來保護藥物的生命週期價值，拓展適應症至疾病進展的早期階段，並提供差異化服務，例如藥物援助計劃和綜合患者支持。核准的非專利策略旨在平衡消費者對低成本替代品的需求與品牌藥通路關係，而完全無品牌非專利則帶來了傳統的價格競爭和分銷最佳化壓力。

在不斷變化的腫瘤學環境中，採取切實可行的戰術性步驟和策略重點，以確保臨床定位、供應連續性和與支付方的協調一致。

產業領導者應迅速調整其臨床、商業和營運策略，以適應不斷變化的治療和政策環境。首先，他們應闡明自身的比較優勢，優先進行符合支付方證據要求的研究，關注對臨床醫生和醫療系統至關重要的療效指標，並支持藥品目錄和指南的採納。其次，他們應透過供應商多元化、評估近岸外包方案以及加強庫存分析來增強分銷管道的韌性，從而減輕貿易政策變化對營運的影響。第三，他們應發展差異化的病人和醫護人員支持模式，以提高病人的用藥依從性，減少行政管理的摩擦，並向相關人員展現實際價值。

本分析所依據的調查方法嚴謹，結合了專家訪談、監管和臨床文獻綜合以及交叉檢驗三角測量，從而提供策略性見解。

本分析所依據的研究結合了第一手和第二手研究方法，以確保對臨床、商業性和營運動態有全面且平衡的理解。第一手研究包括對臨床意見領袖、處方集、醫院藥屋主任和分銷主管進行結構化訪談，以收集關於臨床應用、准入挑戰和運營實踐的第一手觀點。第二手研究涵蓋監管文件、同行評審文獻、臨床試驗註冊庫和公共資訊來源，檢驗了標籤趨勢、指南更新和貿易政策變化。透過對這些資訊檢驗，確保策略推理既有實證證據支持，又有實務經驗支持。

整合策略意義，確保永續獲取：強調基於證據的差異化、供應鏈韌性和相關人員的綜合協作

累積分析凸顯了當前市場環境的複雜性和動態性。臨床進展不斷拓展治療可能性，而監管、競爭和貿易等因素也帶來了執行上的挑戰。關鍵主題包括：需要基於實證醫學進行差異化；在貿易政策不斷變化的情況下，建立具有韌性和多元化的供應鏈至關重要；以及針對不同終端使用者和分銷管道製定客製化商業化策略的核心意義。未來，成功將越來越依賴一種能夠整合臨床開發、支付方證據、區域監管策略以及營運準備情況的策略，從而確保患者能夠持續獲得治療。

目錄

第1章：序言

第2章調查方法

  • 研究設計
  • 研究框架
  • 市場規模預測
  • 數據三角測量
  • 調查結果
  • 調查前提
  • 調查限制

第3章執行摘要

  • 首席體驗長觀點
  • 市場規模和成長趨勢
  • 2025年市佔率分析
  • FPNV定位矩陣，2025
  • 新的商機
  • 下一代經營模式
  • 產業藍圖

第4章 市場概覽

  • 產業生態系與價值鏈分析
  • 波特五力分析
  • PESTEL 分析
  • 市場展望
  • 市場進入策略

第5章 市場洞察

  • 消費者洞察與終端用戶觀點
  • 消費者體驗基準
  • 機會地圖
  • 分銷通路分析
  • 價格趨勢分析
  • 監理合規和標準框架
  • ESG與永續性分析
  • 中斷和風險情景
  • 投資報酬率和成本效益分析

第6章：美國關稅的累積影響，2025年

第7章：人工智慧的累積影響，2025年

第8章Enzalutamide藥物市場（依品牌類型分類）

  • 品牌產品
  • 學名藥

第9章Enzalutamide藥物市場（依適應症分類）

  • 轉移性去勢去勢抗性前列腺癌
  • 轉移性荷爾蒙敏感性前列腺癌
  • 非轉移性去勢抗性前列腺癌

第10章Enzalutamide藥物市場按劑型分類

  • 膠囊
  • 液體
  • 藥片

第11章Enzalutamide藥物市場（以劑量強度分類）

  • 20毫克
  • 40毫克

第12章Enzalutamide藥物市場：依最終用戶分類

  • 醫院
    • 私立醫院
    • 公立醫院
  • 零售藥房
  • 專科癌症中心

第13章Enzalutamide藥物市場（依通路分類）

  • 離線
  • 線上

第14章Enzalutamide藥物市場（按地區分類）

  • 美洲
    • 北美洲
    • 拉丁美洲
  • 歐洲、中東和非洲
    • 歐洲
    • 中東
    • 非洲
  • 亞太地區

第15章Enzalutamide藥物市場：依組別分類

  • ASEAN
  • GCC
  • EU
  • BRICS
  • G7
  • NATO

第16章 各國Enzalutamide藥物市場概況

  • 美國
  • 加拿大
  • 墨西哥
  • 巴西
  • 英國
  • 德國
  • 法國
  • 俄羅斯
  • 義大利
  • 西班牙
  • 中國
  • 印度
  • 日本
  • 澳洲
  • 韓國

第17章：美國Enzalutamide藥物市場

第18章：中國Enzalutamide藥物市場

第19章 競爭情勢

  • 市場集中度分析，2025年
    • 濃度比（CR）
    • 赫芬達爾-赫希曼指數 (HHI)
  • 近期趨勢及影響分析，2025 年
  • 2025年產品系列分析
  • 基準分析，2025 年
  • Aarti Pharmalabs Limited
  • Aprazer Healthcare Private Limited
  • Astellas Pharma Inc.
  • BDR Pharmaceuticals International Private Limited
  • Cipla Limited
  • Dr. Reddy's Laboratories Limited
  • Glenmark Pharmaceuticals Limited
  • Hetero Healthcare Limited
  • Hunan Huateng Pharmaceutical Co., Ltd.
  • Intas Pharmaceuticals Limited
  • Laurus Labs Limited
  • MSN Laboratories Private Limited
  • Pfizer Inc.
  • RPG Life Sciences Limited
  • Shilpa Medicare Limited
  • Shivalik Rasayan Limited
  • Sun Pharmaceutical Industries Limited
  • Viatris Inc.
  • Zaklady Farmaceutyczne Polpharma SA
  • Zydus Lifesciences Limited
Product Code: MRR-7A380DA7C40A

The Enzalutamide Drugs Market was valued at USD 6.97 billion in 2025 and is projected to grow to USD 7.50 billion in 2026, with a CAGR of 8.71%, reaching USD 12.51 billion by 2032.

KEY MARKET STATISTICS
Base Year [2025] USD 6.97 billion
Estimated Year [2026] USD 7.50 billion
Forecast Year [2032] USD 12.51 billion
CAGR (%) 8.71%

A strategic introduction that situates enzalutamide within evolving clinical practice, payer priorities, and competitive lifecycle management dynamics

Enzalutamide has become a central therapeutic option in contemporary prostate cancer care, influencing treatment pathways across multiple disease states. Recent shifts in clinical practice, regulatory approvals, and competitive entry have expanded the clinical conversation beyond late-stage metastatic disease to earlier treatment settings and adjuvant contexts. As a consequence, stakeholders across the value chain-clinicians, payers, manufacturers, and specialty pharmacies-must synthesize evolving evidence with operational realities to determine positioning, access, and supply strategies. This introduction frames the broader landscape by outlining core pharmacologic attributes, prevailing clinical roles, and the strategic imperatives that define stakeholder priorities.

Clinicians and oncology program leaders are balancing efficacy, tolerability, and sequencing considerations as new comparative evidence accumulates. Payers and health systems are recalibrating formularies and prior authorization protocols to incorporate real-world effectiveness and value-based considerations. Manufacturers and distribution partners are adapting their go-to-market approaches to emphasize patient support, adherence solutions, and differentiated service offerings that extend beyond the pill. Moreover, regulatory and intellectual property timelines remain pivotal in determining competitive dynamics, with authorized generics and branded alternatives shaping contracting and procurement strategies. Taken together, these factors create an environment where clear, actionable intelligence is essential for aligning commercial, clinical, and operational plans with the realities of modern oncology care.

How clinical evidence progression, regulatory refinement, and commercial innovation are reshaping enzalutamide use and competitive dynamics

The landscape for enzalutamide has experienced substantive transformative shifts driven by advances in clinical evidence, regulatory actions, and commercial innovation. Clinical trials and real-world studies have extended the therapeutic conversation into earlier disease settings and nuanced patient subgroups, prompting clinicians to reconsider sequencing and combination strategies. Concurrently, regulatory agencies have refined labeling and post-approval requirements, which has influenced prescribing patterns and the evidence manufacturers must generate to sustain utilization. These clinical and regulatory currents have catalyzed changes in commercial models, with an emphasis on patient support programs, digital adherence tools, and integrated care pathways to improve outcomes and reduce friction in access.

Parallel to these clinical and regulatory developments, competitive dynamics have evolved through increased interest in authorized generics and new entrants seeking to address cost and access barriers. Distribution and channel strategies have adapted accordingly: hospital systems and cancer centers are emphasizing integrated oncology pharmacy models while retail and online pharmacies innovate around fulfillment and patient convenience. Payers are increasingly deploying outcomes-based agreements and tailored utilization management to balance access with budgetary stewardship. The resulting environment is one of heightened complexity but also of opportunity, as organizations that align clinical evidence generation with differentiated access and distribution approaches will be better positioned to capture value amid the evolving therapeutic paradigm.

Assessing the operational ripple effects of recent tariff adjustments on sourcing strategies, supply chain resilience, and distribution models for oncology therapies

The introduction of enhanced tariff measures and trade policy updates in the United States has introduced new considerations for manufacturers, distributors, and healthcare providers involved with critical oncology therapies. Changes in tariff classifications, adjustments to import duties on active pharmaceutical ingredients, and tightened scrutiny of cross-border supply chains have influenced sourcing decisions and cost-to-serve analyses. These policy shifts have encouraged organizations to reevaluate their manufacturing footprints, supplier diversification strategies, and inventory management policies to reduce exposure to trade-related volatility while maintaining continuity of care for patients reliant on therapeutic consistency.

In response, many manufacturers have accelerated nearshoring initiatives and sought greater vertical integration of critical supply chain nodes. Contract manufacturers and ingredient suppliers are being assessed not only on traditional quality and cost metrics but also on resiliency under new trade regimes. Distribution partners have adapted contractual terms to reflect greater risk-sharing and to ensure transparent pass-through of tariff impacts where applicable. Health systems and oncology providers are adjusting procurement practices, increasing buffer stocks for critical therapies, and collaborating more closely with suppliers to avoid supply disruptions. Collectively, these measures reflect a broader strategic recalibration that prioritizes supply chain resilience and operational continuity in the face of evolving trade policy dynamics.

Comprehensive segmentation insights linking indication nuances, brand typologies, end user behaviors, and channel distinctions to strategic market actions

A granular understanding of segmentation is essential to navigating the enzalutamide landscape and tailoring commercial and clinical strategies across patient cohorts, channel partners, and product configurations. Based on indication, stakeholders must differentiate value propositions for metastatic castration-resistant prostate cancer, metastatic hormone-sensitive prostate cancer, and non-metastatic castration-resistant prostate cancer, since each indication carries distinct clinical endpoints, treatment sequencing considerations, and payer evaluation criteria. Based on brand type, strategic choices differ markedly between authorized generic offerings, branded formulations, and fully unbranded generics, affecting contracting, pricing strategies, and patient support investments. Based on end user, supply and service models vary across hospitals, retail pharmacies, and specialized cancer centers, with hospitals further divided into private and public settings and specialized cancer centers split between academic and private oncology centers, each presenting unique purchasing practices, clinical trial linkages, and formulary governance.

Based on distribution channel, stakeholders must design differentiated approaches for hospital pharmacies, online pharmacies, retail pharmacies, and wholesale distributors, with further nuance between general and oncology hospital pharmacies, manufacturer direct and third-party online models, chain versus independent retail formats, and national versus regional distributors. Based on formulation, market access and patient adherence strategies differ for capsules, solutions, and tablets, and packaging formats such as blister versus bottle packs for capsules or film coated versus uncoated tablets can influence dispensing preferences and patient experience. Finally, based on dosage strength, clinical usage patterns and packaging decisions diverge across twenty milligram and forty milligram strengths, with the forty milligram strength presenting additional considerations when offered in multi-dose versus single-dose packaging. Strategically integrating these segmentation lenses enables more precise targeting of clinical evidence generation, contracting, and distribution investments.

How regional regulatory diversity, payer ecosystems, and distribution infrastructures create differentiated pathways to access across global markets

Regional dynamics are instrumental in shaping access pathways, regulatory interactions, and commercial strategies, with distinct characteristics evident across the Americas, Europe, Middle East & Africa, and Asia-Pacific. In the Americas, market access tends to be driven by a mix of private payers and public programs, with established oncology networks and oncology-focused pharmacies playing a central role in distribution and patient support. Payer negotiations and value dossiers commonly determine formulary placement, while clinical guideline adoption and academic center influence can accelerate uptake in specific indications. In contrast, Europe, Middle East & Africa presents a heterogeneous mix of regulatory frameworks and reimbursement environments where centralized and country-level assessment mechanisms coexist, creating variable access timelines and diverse pricing pressures.

Asia-Pacific encompasses a wide spectrum of development and access realities, from highly regulated markets with strong pharmacovigilance systems to emerging markets where supply chain constraints and affordability considerations are more pronounced. Across these regions, regulatory expectations for local evidence generation, pricing transparency, and patient assistance programs vary, requiring manufacturers to develop region-specific strategies that balance global standards with local operational realities. Collaboration with local clinical leaders, tailored health economic submissions, and adaptive distribution models are recurrent themes that influence successful regional execution. Navigating these geographic distinctions demands both centralized strategic coherence and decentralized operational agility to respond to regulatory and payer idiosyncrasies.

Competitive dynamics and partnership models highlighting how innovators, authorized generics, and service providers are shaping therapeutic differentiation

Competitive activity in the enzalutamide space is characterized by a mix of established innovators, authorized generic entrants, specialized manufacturers, and contract services providers, each contributing to an increasingly layered competitive landscape. Innovator companies focus on protecting lifecycle value through post-approval trials, label expansions into earlier disease settings, and service-based differentiation such as adherence programs and integrated patient support. Authorized generic strategies are being deployed to balance demand for lower-cost alternatives while preserving branded channel relationships, and fully unbranded generics introduce traditional price competition and distribution optimization pressures.

Strategic alliances, licensing agreements, and manufacturing partnerships are common as firms seek to secure supply security, extend geographic reach, and accelerate commercialization timelines. Contract manufacturing organizations and specialized distributors play a growing role in enabling scale, improving cost structures, and supporting compliance with evolving quality and trade policies. At the same time, newer entrants and smaller specialty firms emphasize nimble commercialization tactics and targeted relationship building with cancer centers and payers. Across the competitive spectrum, differentiation increasingly hinges on value-added services-such as real-world evidence initiatives, digital adherence tools, and patient financial navigation-that complement the core therapeutic offering and influence uptake across diverse care settings.

Practical tactical moves and strategic priorities to secure clinical positioning, supply continuity, and payer alignment in a shifting oncology environment

Industry leaders should act decisively to align clinical, commercial, and operational strategies with the evolving therapeutic and policy environment. First, prioritize evidence generation that clarifies comparative positioning and addresses payer evidence requirements, focusing on outcomes that matter to clinicians and health systems to support formulary inclusion and guideline adoption. Second, invest in distribution resilience by diversifying supplier bases, evaluating nearshoring options, and enhancing inventory analytics to mitigate the operational impact of trade policy shifts. Third, develop differentiated patient and provider support models that improve adherence, reduce administrative friction, and demonstrate real-world value to stakeholders.

Additionally, adapt pricing and contracting approaches to reflect the competitive presence of authorized generics and unbranded alternatives by exploring value-based contracting and risk-sharing arrangements where appropriate. Strengthen regional strategies through tailored regulatory plans and local stakeholder engagement, ensuring that health economic evidence and real-world data address local payer concerns. Finally, prioritize partnerships with specialty pharmacies, academic centers, and clinical networks to accelerate voice-of-clinician feedback loops and to support targeted education initiatives. By integrating these priority actions, industry leaders can better manage uncertainty, protect clinical positioning, and drive sustainable access across complex market environments.

Methodological rigor combining primary expert interviews, regulatory and clinical literature synthesis, and cross-validated triangulation to inform strategic insights

The research underpinning this analysis synthesizes primary and secondary methodologies to ensure a robust, balanced understanding of clinical, commercial, and operational dynamics. Primary research included structured interviews with clinical opinion leaders, formulary decision-makers, hospital pharmacy directors, and distribution executives to capture on-the-ground perspectives about clinical use, access challenges, and operational practices. Secondary research encompassed regulatory documents, peer-reviewed literature, clinical trial registries, and public policy sources to validate trends in labeling, guideline updates, and trade policy changes. Triangulation of these inputs ensured that strategic inferences were grounded in both empirical evidence and practitioner insight.

Data integrity was maintained through cross-validation across multiple independent sources and by subjecting thematic findings to expert review. Segmentation analysis incorporated both clinical and commercial lenses to reflect the multifaceted nature of therapeutic adoption and channel behaviors, while regional analysis relied on local regulatory documentation and payer guidance to reflect jurisdictional differences. The methodology emphasized transparency in assumptions and a clear audit trail for insights to facilitate external validation and application by commercial and medical teams. Together, these methods provide a defensible basis for the strategic implications and recommendations presented.

Synthesis of strategic implications emphasizing evidence-driven differentiation, supply chain resilience, and integrated stakeholder collaboration for sustained access

The cumulative analysis highlights a market environment that is simultaneously dynamic and delicate, where clinical advances expand therapeutic potential while regulatory, competitive, and trade variables introduce material executional complexity. Key themes include the necessity of evidence-driven differentiation, the importance of resilient and diversified supply chains in the face of changing trade policy, and the centrality of tailored commercialization strategies across distinct end users and distribution channels. Success will increasingly rely on an integrated approach that aligns clinical development with payer evidence, regional regulatory strategies, and operational readiness to deliver consistent patient access.

Looking ahead, organizations that proactively invest in robust real-world evidence programs, cultivate flexible manufacturing and distribution capabilities, and build differentiated service models for providers and patients will be better positioned to navigate uncertainty. Collaborative engagement across the ecosystem-bringing clinicians, payers, distributors, and manufacturers into earlier and more structured dialogues-will accelerate problem-solving and reduce time-to-access for patients. Ultimately, strategic foresight combined with operational discipline will determine which stakeholders can sustain clinical relevance and commercial viability in a rapidly evolving therapeutic landscape.

Table of Contents

1. Preface

  • 1.1. Objectives of the Study
  • 1.2. Market Definition
  • 1.3. Market Segmentation & Coverage
  • 1.4. Years Considered for the Study
  • 1.5. Currency Considered for the Study
  • 1.6. Language Considered for the Study
  • 1.7. Key Stakeholders

2. Research Methodology

  • 2.1. Introduction
  • 2.2. Research Design
    • 2.2.1. Primary Research
    • 2.2.2. Secondary Research
  • 2.3. Research Framework
    • 2.3.1. Qualitative Analysis
    • 2.3.2. Quantitative Analysis
  • 2.4. Market Size Estimation
    • 2.4.1. Top-Down Approach
    • 2.4.2. Bottom-Up Approach
  • 2.5. Data Triangulation
  • 2.6. Research Outcomes
  • 2.7. Research Assumptions
  • 2.8. Research Limitations

3. Executive Summary

  • 3.1. Introduction
  • 3.2. CXO Perspective
  • 3.3. Market Size & Growth Trends
  • 3.4. Market Share Analysis, 2025
  • 3.5. FPNV Positioning Matrix, 2025
  • 3.6. New Revenue Opportunities
  • 3.7. Next-Generation Business Models
  • 3.8. Industry Roadmap

4. Market Overview

  • 4.1. Introduction
  • 4.2. Industry Ecosystem & Value Chain Analysis
    • 4.2.1. Supply-Side Analysis
    • 4.2.2. Demand-Side Analysis
    • 4.2.3. Stakeholder Analysis
  • 4.3. Porter's Five Forces Analysis
  • 4.4. PESTLE Analysis
  • 4.5. Market Outlook
    • 4.5.1. Near-Term Market Outlook (0-2 Years)
    • 4.5.2. Medium-Term Market Outlook (3-5 Years)
    • 4.5.3. Long-Term Market Outlook (5-10 Years)
  • 4.6. Go-to-Market Strategy

5. Market Insights

  • 5.1. Consumer Insights & End-User Perspective
  • 5.2. Consumer Experience Benchmarking
  • 5.3. Opportunity Mapping
  • 5.4. Distribution Channel Analysis
  • 5.5. Pricing Trend Analysis
  • 5.6. Regulatory Compliance & Standards Framework
  • 5.7. ESG & Sustainability Analysis
  • 5.8. Disruption & Risk Scenarios
  • 5.9. Return on Investment & Cost-Benefit Analysis

6. Cumulative Impact of United States Tariffs 2025

7. Cumulative Impact of Artificial Intelligence 2025

8. Enzalutamide Drugs Market, by Brand Type

  • 8.1. Branded
  • 8.2. Generic

9. Enzalutamide Drugs Market, by Indication

  • 9.1. Metastatic Castration-Resistant Prostate Cancer
  • 9.2. Metastatic Hormone-Sensitive Prostate Cancer
  • 9.3. Non-Metastatic Castration-Resistant Prostate Cancer

10. Enzalutamide Drugs Market, by Formulation

  • 10.1. Capsules
  • 10.2. Solution
  • 10.3. Tablet

11. Enzalutamide Drugs Market, by Dosage Strength

  • 11.1. 20 Milligram
  • 11.2. 40 Milligram

12. Enzalutamide Drugs Market, by End User

  • 12.1. Hospitals
    • 12.1.1. Private Hospitals
    • 12.1.2. Public Hospitals
  • 12.2. Retail Pharmacies
  • 12.3. Specialized Cancer Centers

13. Enzalutamide Drugs Market, by Distribution Channel

  • 13.1. Offline
  • 13.2. Online

14. Enzalutamide Drugs Market, by Region

  • 14.1. Americas
    • 14.1.1. North America
    • 14.1.2. Latin America
  • 14.2. Europe, Middle East & Africa
    • 14.2.1. Europe
    • 14.2.2. Middle East
    • 14.2.3. Africa
  • 14.3. Asia-Pacific

15. Enzalutamide Drugs Market, by Group

  • 15.1. ASEAN
  • 15.2. GCC
  • 15.3. European Union
  • 15.4. BRICS
  • 15.5. G7
  • 15.6. NATO

16. Enzalutamide Drugs Market, by Country

  • 16.1. United States
  • 16.2. Canada
  • 16.3. Mexico
  • 16.4. Brazil
  • 16.5. United Kingdom
  • 16.6. Germany
  • 16.7. France
  • 16.8. Russia
  • 16.9. Italy
  • 16.10. Spain
  • 16.11. China
  • 16.12. India
  • 16.13. Japan
  • 16.14. Australia
  • 16.15. South Korea

17. United States Enzalutamide Drugs Market

18. China Enzalutamide Drugs Market

19. Competitive Landscape

  • 19.1. Market Concentration Analysis, 2025
    • 19.1.1. Concentration Ratio (CR)
    • 19.1.2. Herfindahl Hirschman Index (HHI)
  • 19.2. Recent Developments & Impact Analysis, 2025
  • 19.3. Product Portfolio Analysis, 2025
  • 19.4. Benchmarking Analysis, 2025
  • 19.5. Aarti Pharmalabs Limited
  • 19.6. Aprazer Healthcare Private Limited
  • 19.7. Astellas Pharma Inc.
  • 19.8. BDR Pharmaceuticals International Private Limited
  • 19.9. Cipla Limited
  • 19.10. Dr. Reddy's Laboratories Limited
  • 19.11. Glenmark Pharmaceuticals Limited
  • 19.12. Hetero Healthcare Limited
  • 19.13. Hunan Huateng Pharmaceutical Co., Ltd.
  • 19.14. Intas Pharmaceuticals Limited
  • 19.15. Laurus Labs Limited
  • 19.16. MSN Laboratories Private Limited
  • 19.17. Pfizer Inc.
  • 19.18. RPG Life Sciences Limited
  • 19.19. Shilpa Medicare Limited
  • 19.20. Shivalik Rasayan Limited
  • 19.21. Sun Pharmaceutical Industries Limited
  • 19.22. Viatris Inc.
  • 19.23. Zaklady Farmaceutyczne Polpharma S.A.
  • 19.24. Zydus Lifesciences Limited

LIST OF FIGURES

  • FIGURE 1. GLOBAL ENZALUTAMIDE DRUGS MARKET SIZE, 2018-2032 (USD MILLION)
  • FIGURE 2. GLOBAL ENZALUTAMIDE DRUGS MARKET SHARE, BY KEY PLAYER, 2025
  • FIGURE 3. GLOBAL ENZALUTAMIDE DRUGS MARKET, FPNV POSITIONING MATRIX, 2025
  • FIGURE 4. GLOBAL ENZALUTAMIDE DRUGS MARKET SIZE, BY BRAND TYPE, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 5. GLOBAL ENZALUTAMIDE DRUGS MARKET SIZE, BY INDICATION, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 6. GLOBAL ENZALUTAMIDE DRUGS MARKET SIZE, BY FORMULATION, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 7. GLOBAL ENZALUTAMIDE DRUGS MARKET SIZE, BY DOSAGE STRENGTH, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 8. GLOBAL ENZALUTAMIDE DRUGS MARKET SIZE, BY END USER, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 9. GLOBAL ENZALUTAMIDE DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 10. GLOBAL ENZALUTAMIDE DRUGS MARKET SIZE, BY REGION, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 11. GLOBAL ENZALUTAMIDE DRUGS MARKET SIZE, BY GROUP, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 12. GLOBAL ENZALUTAMIDE DRUGS MARKET SIZE, BY COUNTRY, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 13. UNITED STATES ENZALUTAMIDE DRUGS MARKET SIZE, 2018-2032 (USD MILLION)
  • FIGURE 14. CHINA ENZALUTAMIDE DRUGS MARKET SIZE, 2018-2032 (USD MILLION)

LIST OF TABLES

  • TABLE 1. GLOBAL ENZALUTAMIDE DRUGS MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 2. GLOBAL ENZALUTAMIDE DRUGS MARKET SIZE, BY BRAND TYPE, 2018-2032 (USD MILLION)
  • TABLE 3. GLOBAL ENZALUTAMIDE DRUGS MARKET SIZE, BY BRANDED, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 4. GLOBAL ENZALUTAMIDE DRUGS MARKET SIZE, BY BRANDED, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 5. GLOBAL ENZALUTAMIDE DRUGS MARKET SIZE, BY BRANDED, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 6. GLOBAL ENZALUTAMIDE DRUGS MARKET SIZE, BY GENERIC, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 7. GLOBAL ENZALUTAMIDE DRUGS MARKET SIZE, BY GENERIC, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 8. GLOBAL ENZALUTAMIDE DRUGS MARKET SIZE, BY GENERIC, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 9. GLOBAL ENZALUTAMIDE DRUGS MARKET SIZE, BY INDICATION, 2018-2032 (USD MILLION)
  • TABLE 10. GLOBAL ENZALUTAMIDE DRUGS MARKET SIZE, BY METASTATIC CASTRATION-RESISTANT PROSTATE CANCER, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 11. GLOBAL ENZALUTAMIDE DRUGS MARKET SIZE, BY METASTATIC CASTRATION-RESISTANT PROSTATE CANCER, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 12. GLOBAL ENZALUTAMIDE DRUGS MARKET SIZE, BY METASTATIC CASTRATION-RESISTANT PROSTATE CANCER, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 13. GLOBAL ENZALUTAMIDE DRUGS MARKET SIZE, BY METASTATIC HORMONE-SENSITIVE PROSTATE CANCER, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 14. GLOBAL ENZALUTAMIDE DRUGS MARKET SIZE, BY METASTATIC HORMONE-SENSITIVE PROSTATE CANCER, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 15. GLOBAL ENZALUTAMIDE DRUGS MARKET SIZE, BY METASTATIC HORMONE-SENSITIVE PROSTATE CANCER, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 16. GLOBAL ENZALUTAMIDE DRUGS MARKET SIZE, BY NON-METASTATIC CASTRATION-RESISTANT PROSTATE CANCER, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 17. GLOBAL ENZALUTAMIDE DRUGS MARKET SIZE, BY NON-METASTATIC CASTRATION-RESISTANT PROSTATE CANCER, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 18. GLOBAL ENZALUTAMIDE DRUGS MARKET SIZE, BY NON-METASTATIC CASTRATION-RESISTANT PROSTATE CANCER, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 19. GLOBAL ENZALUTAMIDE DRUGS MARKET SIZE, BY FORMULATION, 2018-2032 (USD MILLION)
  • TABLE 20. GLOBAL ENZALUTAMIDE DRUGS MARKET SIZE, BY CAPSULES, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 21. GLOBAL ENZALUTAMIDE DRUGS MARKET SIZE, BY CAPSULES, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 22. GLOBAL ENZALUTAMIDE DRUGS MARKET SIZE, BY CAPSULES, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 23. GLOBAL ENZALUTAMIDE DRUGS MARKET SIZE, BY SOLUTION, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 24. GLOBAL ENZALUTAMIDE DRUGS MARKET SIZE, BY SOLUTION, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 25. GLOBAL ENZALUTAMIDE DRUGS MARKET SIZE, BY SOLUTION, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 26. GLOBAL ENZALUTAMIDE DRUGS MARKET SIZE, BY TABLET, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 27. GLOBAL ENZALUTAMIDE DRUGS MARKET SIZE, BY TABLET, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 28. GLOBAL ENZALUTAMIDE DRUGS MARKET SIZE, BY TABLET, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 29. GLOBAL ENZALUTAMIDE DRUGS MARKET SIZE, BY DOSAGE STRENGTH, 2018-2032 (USD MILLION)
  • TABLE 30. GLOBAL ENZALUTAMIDE DRUGS MARKET SIZE, BY 20 MILLIGRAM, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 31. GLOBAL ENZALUTAMIDE DRUGS MARKET SIZE, BY 20 MILLIGRAM, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 32. GLOBAL ENZALUTAMIDE DRUGS MARKET SIZE, BY 20 MILLIGRAM, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 33. GLOBAL ENZALUTAMIDE DRUGS MARKET SIZE, BY 40 MILLIGRAM, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 34. GLOBAL ENZALUTAMIDE DRUGS MARKET SIZE, BY 40 MILLIGRAM, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 35. GLOBAL ENZALUTAMIDE DRUGS MARKET SIZE, BY 40 MILLIGRAM, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 36. GLOBAL ENZALUTAMIDE DRUGS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 37. GLOBAL ENZALUTAMIDE DRUGS MARKET SIZE, BY HOSPITALS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 38. GLOBAL ENZALUTAMIDE DRUGS MARKET SIZE, BY HOSPITALS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 39. GLOBAL ENZALUTAMIDE DRUGS MARKET SIZE, BY HOSPITALS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 40. GLOBAL ENZALUTAMIDE DRUGS MARKET SIZE, BY HOSPITALS, 2018-2032 (USD MILLION)
  • TABLE 41. GLOBAL ENZALUTAMIDE DRUGS MARKET SIZE, BY PRIVATE HOSPITALS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 42. GLOBAL ENZALUTAMIDE DRUGS MARKET SIZE, BY PRIVATE HOSPITALS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 43. GLOBAL ENZALUTAMIDE DRUGS MARKET SIZE, BY PRIVATE HOSPITALS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 44. GLOBAL ENZALUTAMIDE DRUGS MARKET SIZE, BY PUBLIC HOSPITALS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 45. GLOBAL ENZALUTAMIDE DRUGS MARKET SIZE, BY PUBLIC HOSPITALS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 46. GLOBAL ENZALUTAMIDE DRUGS MARKET SIZE, BY PUBLIC HOSPITALS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 47. GLOBAL ENZALUTAMIDE DRUGS MARKET SIZE, BY RETAIL PHARMACIES, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 48. GLOBAL ENZALUTAMIDE DRUGS MARKET SIZE, BY RETAIL PHARMACIES, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 49. GLOBAL ENZALUTAMIDE DRUGS MARKET SIZE, BY RETAIL PHARMACIES, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 50. GLOBAL ENZALUTAMIDE DRUGS MARKET SIZE, BY SPECIALIZED CANCER CENTERS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 51. GLOBAL ENZALUTAMIDE DRUGS MARKET SIZE, BY SPECIALIZED CANCER CENTERS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 52. GLOBAL ENZALUTAMIDE DRUGS MARKET SIZE, BY SPECIALIZED CANCER CENTERS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 53. GLOBAL ENZALUTAMIDE DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 54. GLOBAL ENZALUTAMIDE DRUGS MARKET SIZE, BY OFFLINE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 55. GLOBAL ENZALUTAMIDE DRUGS MARKET SIZE, BY OFFLINE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 56. GLOBAL ENZALUTAMIDE DRUGS MARKET SIZE, BY OFFLINE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 57. GLOBAL ENZALUTAMIDE DRUGS MARKET SIZE, BY ONLINE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 58. GLOBAL ENZALUTAMIDE DRUGS MARKET SIZE, BY ONLINE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 59. GLOBAL ENZALUTAMIDE DRUGS MARKET SIZE, BY ONLINE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 60. GLOBAL ENZALUTAMIDE DRUGS MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 61. AMERICAS ENZALUTAMIDE DRUGS MARKET SIZE, BY SUBREGION, 2018-2032 (USD MILLION)
  • TABLE 62. AMERICAS ENZALUTAMIDE DRUGS MARKET SIZE, BY BRAND TYPE, 2018-2032 (USD MILLION)
  • TABLE 63. AMERICAS ENZALUTAMIDE DRUGS MARKET SIZE, BY INDICATION, 2018-2032 (USD MILLION)
  • TABLE 64. AMERICAS ENZALUTAMIDE DRUGS MARKET SIZE, BY FORMULATION, 2018-2032 (USD MILLION)
  • TABLE 65. AMERICAS ENZALUTAMIDE DRUGS MARKET SIZE, BY DOSAGE STRENGTH, 2018-2032 (USD MILLION)
  • TABLE 66. AMERICAS ENZALUTAMIDE DRUGS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 67. AMERICAS ENZALUTAMIDE DRUGS MARKET SIZE, BY HOSPITALS, 2018-2032 (USD MILLION)
  • TABLE 68. AMERICAS ENZALUTAMIDE DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 69. NORTH AMERICA ENZALUTAMIDE DRUGS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 70. NORTH AMERICA ENZALUTAMIDE DRUGS MARKET SIZE, BY BRAND TYPE, 2018-2032 (USD MILLION)
  • TABLE 71. NORTH AMERICA ENZALUTAMIDE DRUGS MARKET SIZE, BY INDICATION, 2018-2032 (USD MILLION)
  • TABLE 72. NORTH AMERICA ENZALUTAMIDE DRUGS MARKET SIZE, BY FORMULATION, 2018-2032 (USD MILLION)
  • TABLE 73. NORTH AMERICA ENZALUTAMIDE DRUGS MARKET SIZE, BY DOSAGE STRENGTH, 2018-2032 (USD MILLION)
  • TABLE 74. NORTH AMERICA ENZALUTAMIDE DRUGS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 75. NORTH AMERICA ENZALUTAMIDE DRUGS MARKET SIZE, BY HOSPITALS, 2018-2032 (USD MILLION)
  • TABLE 76. NORTH AMERICA ENZALUTAMIDE DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 77. LATIN AMERICA ENZALUTAMIDE DRUGS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 78. LATIN AMERICA ENZALUTAMIDE DRUGS MARKET SIZE, BY BRAND TYPE, 2018-2032 (USD MILLION)
  • TABLE 79. LATIN AMERICA ENZALUTAMIDE DRUGS MARKET SIZE, BY INDICATION, 2018-2032 (USD MILLION)
  • TABLE 80. LATIN AMERICA ENZALUTAMIDE DRUGS MARKET SIZE, BY FORMULATION, 2018-2032 (USD MILLION)
  • TABLE 81. LATIN AMERICA ENZALUTAMIDE DRUGS MARKET SIZE, BY DOSAGE STRENGTH, 2018-2032 (USD MILLION)
  • TABLE 82. LATIN AMERICA ENZALUTAMIDE DRUGS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 83. LATIN AMERICA ENZALUTAMIDE DRUGS MARKET SIZE, BY HOSPITALS, 2018-2032 (USD MILLION)
  • TABLE 84. LATIN AMERICA ENZALUTAMIDE DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 85. EUROPE, MIDDLE EAST & AFRICA ENZALUTAMIDE DRUGS MARKET SIZE, BY SUBREGION, 2018-2032 (USD MILLION)
  • TABLE 86. EUROPE, MIDDLE EAST & AFRICA ENZALUTAMIDE DRUGS MARKET SIZE, BY BRAND TYPE, 2018-2032 (USD MILLION)
  • TABLE 87. EUROPE, MIDDLE EAST & AFRICA ENZALUTAMIDE DRUGS MARKET SIZE, BY INDICATION, 2018-2032 (USD MILLION)
  • TABLE 88. EUROPE, MIDDLE EAST & AFRICA ENZALUTAMIDE DRUGS MARKET SIZE, BY FORMULATION, 2018-2032 (USD MILLION)
  • TABLE 89. EUROPE, MIDDLE EAST & AFRICA ENZALUTAMIDE DRUGS MARKET SIZE, BY DOSAGE STRENGTH, 2018-2032 (USD MILLION)
  • TABLE 90. EUROPE, MIDDLE EAST & AFRICA ENZALUTAMIDE DRUGS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 91. EUROPE, MIDDLE EAST & AFRICA ENZALUTAMIDE DRUGS MARKET SIZE, BY HOSPITALS, 2018-2032 (USD MILLION)
  • TABLE 92. EUROPE, MIDDLE EAST & AFRICA ENZALUTAMIDE DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 93. EUROPE ENZALUTAMIDE DRUGS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 94. EUROPE ENZALUTAMIDE DRUGS MARKET SIZE, BY BRAND TYPE, 2018-2032 (USD MILLION)
  • TABLE 95. EUROPE ENZALUTAMIDE DRUGS MARKET SIZE, BY INDICATION, 2018-2032 (USD MILLION)
  • TABLE 96. EUROPE ENZALUTAMIDE DRUGS MARKET SIZE, BY FORMULATION, 2018-2032 (USD MILLION)
  • TABLE 97. EUROPE ENZALUTAMIDE DRUGS MARKET SIZE, BY DOSAGE STRENGTH, 2018-2032 (USD MILLION)
  • TABLE 98. EUROPE ENZALUTAMIDE DRUGS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 99. EUROPE ENZALUTAMIDE DRUGS MARKET SIZE, BY HOSPITALS, 2018-2032 (USD MILLION)
  • TABLE 100. EUROPE ENZALUTAMIDE DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 101. MIDDLE EAST ENZALUTAMIDE DRUGS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 102. MIDDLE EAST ENZALUTAMIDE DRUGS MARKET SIZE, BY BRAND TYPE, 2018-2032 (USD MILLION)
  • TABLE 103. MIDDLE EAST ENZALUTAMIDE DRUGS MARKET SIZE, BY INDICATION, 2018-2032 (USD MILLION)
  • TABLE 104. MIDDLE EAST ENZALUTAMIDE DRUGS MARKET SIZE, BY FORMULATION, 2018-2032 (USD MILLION)
  • TABLE 105. MIDDLE EAST ENZALUTAMIDE DRUGS MARKET SIZE, BY DOSAGE STRENGTH, 2018-2032 (USD MILLION)
  • TABLE 106. MIDDLE EAST ENZALUTAMIDE DRUGS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 107. MIDDLE EAST ENZALUTAMIDE DRUGS MARKET SIZE, BY HOSPITALS, 2018-2032 (USD MILLION)
  • TABLE 108. MIDDLE EAST ENZALUTAMIDE DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 109. AFRICA ENZALUTAMIDE DRUGS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 110. AFRICA ENZALUTAMIDE DRUGS MARKET SIZE, BY BRAND TYPE, 2018-2032 (USD MILLION)
  • TABLE 111. AFRICA ENZALUTAMIDE DRUGS MARKET SIZE, BY INDICATION, 2018-2032 (USD MILLION)
  • TABLE 112. AFRICA ENZALUTAMIDE DRUGS MARKET SIZE, BY FORMULATION, 2018-2032 (USD MILLION)
  • TABLE 113. AFRICA ENZALUTAMIDE DRUGS MARKET SIZE, BY DOSAGE STRENGTH, 2018-2032 (USD MILLION)
  • TABLE 114. AFRICA ENZALUTAMIDE DRUGS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 115. AFRICA ENZALUTAMIDE DRUGS MARKET SIZE, BY HOSPITALS, 2018-2032 (USD MILLION)
  • TABLE 116. AFRICA ENZALUTAMIDE DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 117. ASIA-PACIFIC ENZALUTAMIDE DRUGS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 118. ASIA-PACIFIC ENZALUTAMIDE DRUGS MARKET SIZE, BY BRAND TYPE, 2018-2032 (USD MILLION)
  • TABLE 119. ASIA-PACIFIC ENZALUTAMIDE DRUGS MARKET SIZE, BY INDICATION, 2018-2032 (USD MILLION)
  • TABLE 120. ASIA-PACIFIC ENZALUTAMIDE DRUGS MARKET SIZE, BY FORMULATION, 2018-2032 (USD MILLION)
  • TABLE 121. ASIA-PACIFIC ENZALUTAMIDE DRUGS MARKET SIZE, BY DOSAGE STRENGTH, 2018-2032 (USD MILLION)
  • TABLE 122. ASIA-PACIFIC ENZALUTAMIDE DRUGS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 123. ASIA-PACIFIC ENZALUTAMIDE DRUGS MARKET SIZE, BY HOSPITALS, 2018-2032 (USD MILLION)
  • TABLE 124. ASIA-PACIFIC ENZALUTAMIDE DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 125. GLOBAL ENZALUTAMIDE DRUGS MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 126. ASEAN ENZALUTAMIDE DRUGS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 127. ASEAN ENZALUTAMIDE DRUGS MARKET SIZE, BY BRAND TYPE, 2018-2032 (USD MILLION)
  • TABLE 128. ASEAN ENZALUTAMIDE DRUGS MARKET SIZE, BY INDICATION, 2018-2032 (USD MILLION)
  • TABLE 129. ASEAN ENZALUTAMIDE DRUGS MARKET SIZE, BY FORMULATION, 2018-2032 (USD MILLION)
  • TABLE 130. ASEAN ENZALUTAMIDE DRUGS MARKET SIZE, BY DOSAGE STRENGTH, 2018-2032 (USD MILLION)
  • TABLE 131. ASEAN ENZALUTAMIDE DRUGS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 132. ASEAN ENZALUTAMIDE DRUGS MARKET SIZE, BY HOSPITALS, 2018-2032 (USD MILLION)
  • TABLE 133. ASEAN ENZALUTAMIDE DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 134. GCC ENZALUTAMIDE DRUGS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 135. GCC ENZALUTAMIDE DRUGS MARKET SIZE, BY BRAND TYPE, 2018-2032 (USD MILLION)
  • TABLE 136. GCC ENZALUTAMIDE DRUGS MARKET SIZE, BY INDICATION, 2018-2032 (USD MILLION)
  • TABLE 137. GCC ENZALUTAMIDE DRUGS MARKET SIZE, BY FORMULATION, 2018-2032 (USD MILLION)
  • TABLE 138. GCC ENZALUTAMIDE DRUGS MARKET SIZE, BY DOSAGE STRENGTH, 2018-2032 (USD MILLION)
  • TABLE 139. GCC ENZALUTAMIDE DRUGS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 140. GCC ENZALUTAMIDE DRUGS MARKET SIZE, BY HOSPITALS, 2018-2032 (USD MILLION)
  • TABLE 141. GCC ENZALUTAMIDE DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 142. EUROPEAN UNION ENZALUTAMIDE DRUGS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 143. EUROPEAN UNION ENZALUTAMIDE DRUGS MARKET SIZE, BY BRAND TYPE, 2018-2032 (USD MILLION)
  • TABLE 144. EUROPEAN UNION ENZALUTAMIDE DRUGS MARKET SIZE, BY INDICATION, 2018-2032 (USD MILLION)
  • TABLE 145. EUROPEAN UNION ENZALUTAMIDE DRUGS MARKET SIZE, BY FORMULATION, 2018-2032 (USD MILLION)
  • TABLE 146. EUROPEAN UNION ENZALUTAMIDE DRUGS MARKET SIZE, BY DOSAGE STRENGTH, 2018-2032 (USD MILLION)
  • TABLE 147. EUROPEAN UNION ENZALUTAMIDE DRUGS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 148. EUROPEAN UNION ENZALUTAMIDE DRUGS MARKET SIZE, BY HOSPITALS, 2018-2032 (USD MILLION)
  • TABLE 149. EUROPEAN UNION ENZALUTAMIDE DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 150. BRICS ENZALUTAMIDE DRUGS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 151. BRICS ENZALUTAMIDE DRUGS MARKET SIZE, BY BRAND TYPE, 2018-2032 (USD MILLION)
  • TABLE 152. BRICS ENZALUTAMIDE DRUGS MARKET SIZE, BY INDICATION, 2018-2032 (USD MILLION)
  • TABLE 153. BRICS ENZALUTAMIDE DRUGS MARKET SIZE, BY FORMULATION, 2018-2032 (USD MILLION)
  • TABLE 154. BRICS ENZALUTAMIDE DRUGS MARKET SIZE, BY DOSAGE STRENGTH, 2018-2032 (USD MILLION)
  • TABLE 155. BRICS ENZALUTAMIDE DRUGS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 156. BRICS ENZALUTAMIDE DRUGS MARKET SIZE, BY HOSPITALS, 2018-2032 (USD MILLION)
  • TABLE 157. BRICS ENZALUTAMIDE DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 158. G7 ENZALUTAMIDE DRUGS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 159. G7 ENZALUTAMIDE DRUGS MARKET SIZE, BY BRAND TYPE, 2018-2032 (USD MILLION)
  • TABLE 160. G7 ENZALUTAMIDE DRUGS MARKET SIZE, BY INDICATION, 2018-2032 (USD MILLION)
  • TABLE 161. G7 ENZALUTAMIDE DRUGS MARKET SIZE, BY FORMULATION, 2018-2032 (USD MILLION)
  • TABLE 162. G7 ENZALUTAMIDE DRUGS MARKET SIZE, BY DOSAGE STRENGTH, 2018-2032 (USD MILLION)
  • TABLE 163. G7 ENZALUTAMIDE DRUGS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 164. G7 ENZALUTAMIDE DRUGS MARKET SIZE, BY HOSPITALS, 2018-2032 (USD MILLION)
  • TABLE 165. G7 ENZALUTAMIDE DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 166. NATO ENZALUTAMIDE DRUGS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 167. NATO ENZALUTAMIDE DRUGS MARKET SIZE, BY BRAND TYPE, 2018-2032 (USD MILLION)
  • TABLE 168. NATO ENZALUTAMIDE DRUGS MARKET SIZE, BY INDICATION, 2018-2032 (USD MILLION)
  • TABLE 169. NATO ENZALUTAMIDE DRUGS MARKET SIZE, BY FORMULATION, 2018-2032 (USD MILLION)
  • TABLE 170. NATO ENZALUTAMIDE DRUGS MARKET SIZE, BY DOSAGE STRENGTH, 2018-2032 (USD MILLION)
  • TABLE 171. NATO ENZALUTAMIDE DRUGS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 172. NATO ENZALUTAMIDE DRUGS MARKET SIZE, BY HOSPITALS, 2018-2032 (USD MILLION)
  • TABLE 173. NATO ENZALUTAMIDE DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 174. GLOBAL ENZALUTAMIDE DRUGS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 175. UNITED STATES ENZALUTAMIDE DRUGS MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 176. UNITED STATES ENZALUTAMIDE DRUGS MARKET SIZE, BY BRAND TYPE, 2018-2032 (USD MILLION)
  • TABLE 177. UNITED STATES ENZALUTAMIDE DRUGS MARKET SIZE, BY INDICATION, 2018-2032 (USD MILLION)
  • TABLE 178. UNITED STATES ENZALUTAMIDE DRUGS MARKET SIZE, BY FORMULATION, 2018-2032 (USD MILLION)
  • TABLE 179. UNITED STATES ENZALUTAMIDE DRUGS MARKET SIZE, BY DOSAGE STRENGTH, 2018-2032 (USD MILLION)
  • TABLE 180. UNITED STATES ENZALUTAMIDE DRUGS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 181. UNITED STATES ENZALUTAMIDE DRUGS MARKET SIZE, BY HOSPITALS, 2018-2032 (USD MILLION)
  • TABLE 182. UNITED STATES ENZALUTAMIDE DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 183. CHINA ENZALUTAMIDE DRUGS MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 184. CHINA ENZALUTAMIDE DRUGS MARKET SIZE, BY BRAND TYPE, 2018-2032 (USD MILLION)
  • TABLE 185. CHINA ENZALUTAMIDE DRUGS MARKET SIZE, BY INDICATION, 2018-2032 (USD MILLION)
  • TABLE 186. CHINA ENZALUTAMIDE DRUGS MARKET SIZE, BY FORMULATION, 2018-2032 (USD MILLION)
  • TABLE 187. CHINA ENZALUTAMIDE DRUGS MARKET SIZE, BY DOSAGE STRENGTH, 2018-2032 (USD MILLION)
  • TABLE 188. CHINA ENZALUTAMIDE DRUGS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 189. CHINA ENZALUTAMIDE DRUGS MARKET SIZE, BY HOSPITALS, 2018-2032 (USD MILLION)
  • TABLE 190. CHINA ENZALUTAMIDE DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)